IMV TAX
IMV Tax is an accounting firm that provides bookkeeping, payroll, financial planning, cash flow, budgeting and consulting services.
IMV TAX
Industry:
Accounting Consulting Financial Services
Address:
College Point, New York, United States
Country:
United States
Website Url:
http://www.imvtax.com
Status:
Active
Contact:
+1-718-321-3441
Email Addresses:
[email protected]
Technology used in webpage:
Apache IPv6 Google Adsense Google Adsense Asynchronous 1and1
Similar Organizations
Bell CPA
Bell CPA is an accounting firm that provides bookkeeping, tax preparation, estate planning, budgeting and consulting services.
Disteldorf
Disteldorf is an accounting firm that provides bookkeeping, compilation, mergers, acquisition, cash flow, budgeting and consulting services.
Official Site Inspections
http://www.imvtax.com
- Host name: 74-208-236-137.elastic-ssl.ui-r.com
- IP address: 74.208.236.137
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago
More informations about "IMV Tax"
About Us - Imvax
Prior to Spark, Mr. Furey served as Senior Vice President and Head of Global Operations at Baxalta, where he transformed the company’s global operations into a first-in-class supply …See details»
Imvax - Crunchbase Company Profile & Funding
Imvax is a biotechnology company focused on the development of novel patient-specific vaccines and immunotherapy strategies. Imvax may be growing as it has successfully raised $23 million to advance clinical trials.See details»
Imvax, Inc. - LinkedIn
Imvax, Inc. Biotechnology Research Philadelphia, Pennsylvania 3,165 followers Imvax is a clinical-stage biotechnology company developing personalized, whole tumor-derived immunotherapies.See details»
Imvax Company Profile 2024: Valuation, Funding
Imvax is headquartered in Philadelphia, PA. What is the size of Imvax? Imvax has 49 total employees. What industry is Imvax in? Imvax’s primary industry is Drug Discovery. Is Imvax a private or public company? Imvax is a Private company. …See details»
Imvax Corporate Overview
• Imvax Phase 1b trial resulted in median PFS of 17.1 months and median OS of 38.2 months in Stupp-eligible patients at the highest dose • 5-year survival of 15% is more than double …See details»
Imvax - Funding, Financials, Valuation & Investors - Crunchbase
Imvax is a biotechnology company focused on the development of novel patient-specific vaccines and immunotherapy strategies. Search Crunchbase. ... How much funding has this …See details»
Imvax - Contacts, Employees, Board Members, Advisors & Alumni
Organization. Imvax . Connect to CRM . Save . Summary. Financials. People. Technology. Signals & News. Similar Companies. Highlights. Employee Profiles 4. Number of Board …See details»
Imvax Company Profile - Office Locations, Competitors, Revenue
Imvax is a biotechnology company that develops vaccines and immunotherapy strategies for the treatment of malignant gliomas and other cancers. It produces IGV-001, an autologous tumor …See details»
Imvax Company Profile: Overview and Full News Analysis
Imvax, Inc. will present blinded safety data from Phase 2b clinical trial of IGV-001 in patients with newly diagnosed glioblastoma (ndGBM) The Company will also present follow-on data from its …See details»
The Transformative Potential of Immunotherapy for Glioblastoma …
Nov 25, 2023 As a corporate partner of the Glioblastoma Research Organization, Imvax demonstrates its commitment to advancing brain cancer research and supporting GBM …See details»
Imvax Provides Corporate Update - Business Wire
Sep 6, 2023 Imvax is a clinical-stage biotechnology company with a unique platform technology, Goldspireâ„¢, focused on delivering personalized, whole tumor-derived immunotherapies …See details»
Life at Imvax - Imvax
Imvax is committed to creating an inclusive community where every individual is treated with dignity and respect. Fostering a culture in which we celebrate and embrace every team …See details»
Phase 2b of a Promising Brain Tumor Clinical Trial Begins
Aug 9, 2023 Imvax’s most advanced program, IGV-001, is currently being evaluated in a Phase 2b clinical trial in newly diagnosed glioblastoma patients. ... Jefferson holds itself accountable, …See details»
Henry Ford Health Doses First Patient in Combination …
DETROIT (July 12, 2023) – Physicians in the Hermelin Brain Tumor Center at Henry Ford Health recently administered the first dose of IGV-001, a combination immunotherapy developed by …See details»
Imvax: Personalized Immunotherapy for Glioblastoma Patients
Imvax is a pioneering clinical biotechnology company developing personalized cancer treatments specifically designed for glioblastoma (GBM) patients. Skip to content GBM Awareness Day is …See details»
Imvax Announces Completion of Enrollment in Phase 2b Clinical …
May 21, 2024 Imvax’s most advanced program, IGV-001, is currently being evaluated in a Phase 2b clinical trial in newly diagnosed glioblastoma patients. Imvax’s portfolio also includes …See details»
Autologous Cell Immunotherapy (IGV-001) with IGF-1R Antisense ...
Dec 7, 2023 IGV-001 is the first product developed using Goldspireâ„¢, Imvax’s proprietary platform (Figure1). IGV-001 is a cellular immunotherapy combination drug product candidate …See details»
Patients & Families - Imvax
What Phase 1 studies has Imvax conducted? To date, two Phase 1 clinical studies of IGV-001 in recurrent GBM and ndGBM have been completed that dosed a total of 46 patients. The larger …See details»
Pipeline - Imvax
Imvax is developing IOC-001 for the treatment of ovarian cancer. Preclinical studies are ongoing. Back to Pipeline. Imvax clinical trials. Imvax’s story began with a physician’s dedicated pursuit …See details»